Please contact us for more information or to learn if you are eligible to participate.
The primary objective is to evaluate the efficacy of different doses of NST-4016 on the resolution of NASH without worsening of fibrosis.
Principal Investigator | Fernando Membreno, MD |
Co-PI | John Rodriguez |
Sponsor | NorthSea Therapeutics B.V. |
Type of Trial | Interventional |